<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03644056</url>
  </required_header>
  <id_info>
    <org_study_id>IMC-001-101</org_study_id>
    <nct_id>NCT03644056</nct_id>
  </id_info>
  <brief_title>Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-001 in Subjects With Metastatic or Locally-advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmuneOncia Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmuneOncia Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety,
      Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-001 in Subjects with
      Metastatic or Locally-advanced Solid Tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IMC-001 is a PD-L1 targeting, fully human monoclonal antibody. The purpose of this study is
      to determine safety and evaluate PK, PD and clinical activity of IMC-001. Multiple dose
      levels of IMC-001 will be tested in subjects with metastatic or locally-advanced solid
      tumors. Data from this study will also help determine the recommended phase 2 dose of
      IMC-001.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 22, 2018</start_date>
  <completion_date type="Actual">May 14, 2020</completion_date>
  <primary_completion_date type="Actual">February 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of DLTs</measure>
    <time_frame>During the first 21 days of treatment</time_frame>
    <description>To investigate the occurrence of DLTs of IMC-001 treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Metastasis</condition>
  <condition>Locally Advanced</condition>
  <arm_group>
    <arm_group_label>IMC-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Dose Level (IMC-001 2 mg/kg etc. every 2 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMC-001</intervention_name>
    <description>Different IMC-001 dose level for each cohort group (IMC-001 2 mg/kg etc. every 2 weeks)</description>
    <arm_group_label>IMC-001</arm_group_label>
    <other_name>Not confirm yet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent Form (ICF).

          2. Adult (19 years or older).

          3. Histologically or cytologically proven metastatic or locally-advanced solid tumors

        Exclusion Criteria:

          1. Treatment with non-permitted drugs (within the past 28 days of Screening), including
             but not limited to systemic immunosuppressive agents, any other investigational
             medicinal product (IMP), anti-coagulant, or live vaccines.

          2. Any prior cancer immunotherapy

          3. Concurrent anticancer treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yun Jeong Song, CMO/CEO</last_name>
    <role>Study Director</role>
    <affiliation>ImmuneOncia Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ImmuneOncia</name>
      <address>
        <city>Yongin-si</city>
        <state>Gyeonggi-do</state>
        <zip>17084</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2018</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IMC-001</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

